<?xml version="1.0" encoding="UTF-8"?>
<p>All patients' demographics including age, gender, and clinical characteristics were collected by trained examiners. Mentation, behavior, and mood were assessed by UPDRS I. Activities of daily life were assessed by the UPDRS part II. Motor symptoms were evaluated by UPDRS III, and the disease stage was evaluated by H-Y. We also recorded the medication and calculated LEDD. Cognitive functions were evaluated by MMSE. The score lower than 26 points indicated a cognitive impairment [
 <xref rid="B18" ref-type="bibr">18</xref>]. WO was one of the motor complications with the manifestation of decline of benefit from each dose of levodopa. We evaluated WO by WOQ-9 [
 <xref rid="B19" ref-type="bibr">19</xref>]. The WOQ-9 was used to define the presence of WO phenomenon as the presence of at least one symptom with improvement after the next dose of antiparkinsonism medication [
 <xref rid="B20" ref-type="bibr">20</xref>]. CCI was widely used to assess the common comorbidity conditions [
 <xref rid="B21" ref-type="bibr">21</xref>].
</p>
